Consolidation Trends Within the Blossoming RegenMed Service Sector

The WuXi acquisition of Apptec (posted last week) is continuing the trend of consolidation in the cell manufacturing sector. It is similar to Lonza’s (a Swiss company) purchase of Cambrex’s biologics division in 2006, and GE’s purchase of Wave Biotech in mid-2007. Lonza is currently the largest manufacturer of cells for therapy, and has process development and manufacturing relationships with many of today’s clinical-stage regenerative medicine companies. GE is making a big splash with a heavy marketing campaign for the Wave bioproduction system and states in the acquisition press release that “Wave Biotech’s single use bioreactors are increasingly being used to enable the manufacture of patient-specific cell and gene therapy products.” GE is no dummy when it comes to acquiring growth companies and it has increasingly moved to a service-based business in the last 10 years. Now that Stem Cells Inc. is planning to purchase Progenitor Cell Therapy, it looks like Cognate Bioservices is the last ‘major’ cell therapy manufacturer still on it’s own.

Advertisements

About jrowley

This blog is about the technology behind Regenerative Medicine - including, but not limited to, stem cells therapies, biomaterial-based devices, as well as tissue engineered products. My name is Jon Rowley. I have been in the Regenerative Medicine field since 1994 (undergraduate research), and have my PhD in Biomedical Engineering from the University of Michigan in Biomedical Engineering. I am currently an employee of Aastrom Biosciences, an adult autologous cell therapy company. You can see my professional creds at: http://www.linkedin.com/myprofile?trk=tab_pro Important Note: Absolutely everything posted in this blog is my personal opinion and is in no way the opinion of my employer, Aastrom Biosciences, or approved by anyone before it is posted. No warranties or other guarantees will be offered as to the quality of the opinions or anything else offered here.
This entry was posted in Apptec, BD, Bioprocessing, Invitrogen, JNJ, Lonza, Manufacturing, Progenitor Cell Therapy, Regenerative Medicine, Stem Cells Inc, WuXi Pharmatech. Bookmark the permalink.

One Response to Consolidation Trends Within the Blossoming RegenMed Service Sector

  1. Jim H says:

    Jon,

    Rumor has it ( actually, substantiated rumor), that Lonza is going to sink another $25 to $35MM into their Cell Therapy business here in Frederick County (Walkersville). A lot of that is funded by their contract manufacturing of Osiris’ products.

    If you’d like to check it out, another “Gateway” blog is going on in Colorado called the Colorado Life Science Deal flow @ http://www.rnaventures.blogspot.com/

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s